Back to Journals » Drug Design, Development and Therapy » Volume 13

A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: the DOLATAV study

Total article views   HTML views PDF downloads Totals
8,899 Dovepress* 7,977+ 1,232 9,209
PubMed Central* 922 155 1,077
Totals 8,899 1,387 10,286
*Since 24 January 2019

View citations on PubMed Central and Google Scholar